Recent trends and advances in novel formulations as an armament in Bcl-2/Bax targeted breast cancer

• Published in: International journal of pharmaceutics Vol. 653; p. 123889
• Main Authors: Samia, Shaikh, Sandeep Chary, Padakanti, Khan, Omar, Kumar Mehra, Neelesh
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 25.03.2024
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis; BCL-2 Inhibitor; bcl-2-Associated X Protein - pharmacology; Breast cancer; Breast Neoplasms - pathology; Cutting-edge technologies; Female; Humans; Peptides; Proto-Oncogene Proteins c-bcl-2; ALL; CLL; Peptides; Bcl-w; EPR; MPN; AUC; IMDM; SLL; 7-AAD; CaP; Cutting-edge technologies; EMA; DLEU2; TNBC; AIF; AML; MM; EE; qRT-PCR; GMO; BH3; PCE; Apaf1; DISC; ROS; IAP; DCFDA; SMBA; Bcl-2; F-127; BC; BRAC 1; FDA; DLBCL; DLS; NOXA; TPGS; NHL; FTIR; GA; SCLC; MMPs; Breast cancer; TME; PLGA; PEG; VDAC; BCL-2 Inhibitor; HER2; PUMA; TEM
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.123889

[Display omitted] Breast cancer (BC) remains a significant health burden worldwide, necessitating the development of innovative therapeutic strategies. The B-cell lymphoma 2 (Bcl-2) family proteins, Bcl-2 and Bax, play a crucial role in regulating apoptosis and thus are promising targets for BC therapy. We focus on the recent advancements in novel formulations that specifically target Bcl-2/Bax pathway to combat BC. It provides an overview on biological functions of Bcl-2/Bax in apoptosis regulation, emphasizing their significance in pathogenesis and progression of the disease while covering the numerous therapeutic approaches aimed at modulating the Bcl-2/Bax pathway, including small-molecule inhibitors, peptides, gene-based therapies and other repurposed drugs harboured onto cutting-edge technologies and nanocarrier systems employed to enhance the targeted delivery of Bcl-2/Bax inhibitors tumor cells. These advanced formulations aim to improve therapeutic efficacy, minimize off-target effects, and overcome drug resistance, offering promising prospects in its treatment. In conclusion, it illuminates the diverse and evolving landscape of novel formulations as an essential armament in targeting these proteins while bridging and unravelling the obscurity of Bcl-2/Bax pathway-targeted drug delivery systems which are presently in their nascent stages of exploration for BC therapy which can benefit researchers, clinicians, and pharmaceutical scientists.